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Abstract
Renal fibrosis plays an important role in the onset and progression of chronic kidney diseases (CKD). Although several
mechanisms underlying renal fibrosis and candidate drugs for its treatment have been identified, the effect of iron chelator
on renal fibrosis remains unclear. In the present study, we examined the effect of an iron chelator, deferoxamine (DFO), on
renal fibrosis in mice with surgically induced unilateral ureter obstruction (UUO). Mice were divided into 4 groups: UUO with
vehicle, UUO with DFO, sham with vehicle, and sham with DFO. One week after surgery, augmented renal tubulointerstitial
fibrosis and the expression of collagen I, III, and IV increased in mice with UUO; these changes were suppressed by DFO
treatment. Similarly, UUO-induced macrophage infiltration of renal interstitial tubules was reduced in UUO mice treated
with DFO. UUO-induced expression of inflammatory cytokines and extracellular matrix proteins was abrogated by DFO
treatment. DFO inhibited the activation of the transforming growth factor-b1 (TGF-b1)-Smad3 pathway in UUO mice. UUO-
induced NADPH oxidase activity and p22phox expression were attenuated by DFO. In the kidneys of UUO mice, divalent
metal transporter 1, ferroportin, and ferritin expression was higher and transferrin receptor expression was lower than in
sham-operated mice. Increased renal iron content was observed in UUO mice, which was reduced by DFO treatment. These
results suggest that iron reduction by DFO prevents renal tubulointerstitial fibrosis by regulating TGF-b-Smad signaling,
oxidative stress, and inflammatory responses.
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Introduction
The incidence of chronic kidney disease (CKD) has increased
worldwide. CKD worsens morbidity and mortality in the general
population [1,2]. Additionally, the progression of CKD results in
end-stage renal failure, which requires treatment by hemodialysis.
Several factors are involved in the onset and progression of CKD.
The process of renal tubulointerstitial fibrosis is characterized by
extracellular matrix deposition, interstitial myofibroblast prolifer-
ation, and the infiltration of inflammatory mononuclear cells,
which are thought to play an important role in the pathogenesis of
CKD [3]. Therefore, preventing renal interstitial fibrosis is
important for inhibiting the progression of CKD.
Iron is an elementary trace metal that is essential for nearly all
organisms. Excess iron, however, causes oxidative stress through
the production of hydroxyl radicals via Fenton/Haber–Weiss
catalytic reactions [4], which in turn cause tissue damage.
Therefore, the level of intracellular iron is regulated by iron
transporters and iron-binding proteins, and iron is stored in
metalloproteins, heme complexes, oxygen carrier proteins, and
other complexes under normal physiological conditions [5].
Patients with iron overload diseases, such as hereditary
hemochromatosis or thalassemia, suffer complications such as
cardiomyopathy, liver cirrhosis, and diabetes mellitus following
ectopic iron accumulation in the heart, liver, and pancreas,
respectively [6]. Recent studies have shown that iron also
contributes to pathology in patients with non-iron overload
disorders such as hepatitis C [7,8] and Alzheimer’s disease
[9,10], and that iron reduction therapy can ameliorate these
disorders [7,8,11,12]. Iron reduction also has preventive effects in
other diseases, including cardiovascular remodeling [13–15],
obesity [16], and diabetes [17,18]. Thus, iron is involved in the
pathogenesis of hereditary iron overload diseases as well as in
various non-iron overload diseases.
In studies of the relationship between kidney disease and iron,
angiotensin II (AngII) administration increased renal iron depo-
sition and altered the expression of renal iron transporters in rats
[19,20]. Dietary iron restriction can prevent renal injury by
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inhibiting mineralocorticoid receptor signaling in rats with CKD
modeled with 5/6 nephrectomy [21,22]. Additionally, we previ-
ously demonstrated the beneficial effects of a low-iron diet on the
progression of diabetic nephropathy [23]. These findings strongly
suggest that iron is involved in renal damage and that iron
reduction ameliorates kidney injury. However, the effect of iron
reduction on renal tubulointerstitial fibrosis remains unclear.
Deferoxamine (DFO), a bacteria-derived siderophore, chelates
iron by binding iron in the blood and excreting it as a DFO-iron
complex in urine or stool [24]. The preventive effects of DFO on
the progression of obesity [16] and AngII-induced cardiovascular
fibrosis have been demonstrated [13,14]. On the other hand, DFO
upregulates hypoxia-inducible factor-1a (HIF-1a) activity [25],
and HIF-1a is an aggravating factor in tubulointerstitial renal
injury [26]. DFO also increases collagen I and tissue inhibitor
metalloproteinase 1 mRNA levels in vitro [27]. Furthermore, iron
chelation abolishes IL-10-mediated protection against renal injury
[28]. Thus, the effect of DFO on kidney disease remains
controversial.
In the present study, we demonstrated that iron chelation using
DFO alleviated renal tubulointerstitial fibrosis in mice with
unilateral ureteral obstruction (UUO). Furthermore, DFO sup-
pressed UUO-induced renal oxidative stress, inflammation, and
transforming growth factor-b1 (TGF-b1)-Smad signaling. Our
results suggest that iron chelation could be a new therapeutic
approach for treating renal fibrosis.
Materials and Methods
Chemicals and Reagents
DFO was purchased from Calbiochem (San Diego, CA, USA).
The following commercially available antibodies were used in this
study: anti-fibronectin (SC-6952), anti-p22phox (SC-20781), anti-
TGF-b1 (SC-146), anti-IL (interleukin)-1b (SC-7884), anti-ferritin
heavy chain (FTH) (SC-14416), anti-ferritin light chain (FTL) (SC-
14422), anti-collagen IA (SC-25974), anti-collagen IIIA (SC-
8780R), and anti-NRAMP2 (divalent metal transporter-1; DMT1)
(SC-30120) antibodies (Santa Cruz Biotechnology, Santa Cruz,
CA, USA); anti-a-smooth muscle actin (aSMA) antibody (A2547)
(Sigma-Aldrich, St. Louis, MO, USA); anti-rat F4/80 antibody
(MCA497GA) (AbD Serotec, Oxford, UK); anti-phospho Smad3
(9520), anti-total Smad3 (9523), and anti-monocyte chemoattrac-
tant protein-1 (MCP-1) (2029) antibodies (Cell Signaling Tech-
nology, Danvers, MA, USA); anti-transferrin receptor 1 (TfR)
antibody (13–6800) (Life Technologies, Carlsbad, CA); anti-
ferroportin (FPN) antibody (MTP11-A) (Alpha Diagnostics, San
Antonio, TX, USA); anti-NADPH oxidase 4 (NOX4) (ab109225)
and anti-collagen IV (ab6586) antibodies (Abcam, Cambridge,
MA); and anti-tubulin antibody (CP06) (Calbiochem, San Diego,
CA, USA) as a loading control.
Experimental Animals and Treatment
All animal experimental procedures were performed in accor-
dance with the guidelines of the Animal Research Committee of
the University of Tokushima Graduate School, and the protocol
was approved by the Tokushima University Institutional Review
Board for animal protection (Permit Number: 12022). Male
C57BL/6J mice were purchased from CLEA Japan Inc. (Tokyo,
Japan). Mice were maintained in a room under conventional
conditions with a regular 12-h light/dark cycle, and were given
free access to food (Type NMF; 10 mg Fe/100 g food; Oriental
Yeast, Tokyo, Japan) during the study. At 8–12 weeks of age, the
mice underwent surgery to induce unilateral ureteral obstruction
(UUO). UUO is a well-established experimental model of
tubulointerstitial fibrosis. Briefly, under pentobarbital anesthesia,
the left ureter was exposed through a lateral incision and ligated
with 3-0 silk at 2 points at the proximal site. In sham mice, the left
ureter was exposed but not ligated. The total operation period was
approximately 10 min. After the operation, the mice were placed
on a heat mat until the animals completely recovered. Sham and
UUO mice were divided into 2 groups and intraperitoneally
injected with vehicle (VEH) or DFO (100 mg?kg21?day21) for 7
days immediately after operation (sham+VEH, N=18; sham+
DFO, N=14; UUO+VEH, N=15; UUO+DFO, N=15).
Peripheral Blood Analysis
Complete blood counts were performed by Shikoku Chuken
Co., Ltd. (Kagawa, Japan).
Histological Analysis
Seven days after surgery, mice were sacrificed by intraperitoneal
injection of excess pentobarbital, and the kidneys were excised
after normal saline perfusion. A portion of each kidney was fixed
Table 1. Body weight, kidney weight, hemoglobin content, and kidney iron content in mice, 7 days after surgery.
Sham with vehicle (n=18) Sham with DFO (n=14) UUO with vehicle (n=15) UUO with DFO (n=15)
Body weight (BW) (g) 26.860.8 25.960.3 26.660.5 26.660.8
Right kidney weight (RKW) (mg) 13664## 13762## 15563**{{ 15863**{{
RKW to BW ratio 5.260.1## 5.360.1## 6.160.1**{{ 6.260.2**{{
Left kidney weight (LKW) (mg) 13565## 13163# 11661**{ 13465#
LKW to BW ratio 5.060.1# 5.060.1# 4.660.1*{ 5.260.2##
Hemoglobin (g/dL) 13.860.3 12.860.1 13.160.3 13.660.2
Hematocrit (%) 42.360.8 39.760.4 40.361.0 41.360.7
Left kidney iron (mg/g kidney tissue) 5.960.6# 4.860.7## 9.061.2*{{ 4.960.6##
Data are the mean 6 SEM, n= 14–18, as indicated.
*P,0.05,
**P,0.01 vs. sham with vehicle;
{P,0.05,
{{P,0.01 vs. sham with DFO;
#P,0.05,
##P,0.01 vs. UUO with vehicle.
doi:10.1371/journal.pone.0089355.t001
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overnight in 4% paraformaldehyde at 4uC and embedded in
paraffin. Samples were cut into 3 mm sections and stained with
Masson’s trichrome to evaluate renal interstitial fibrosis. Fourteen
fields were randomly selected in 5 different sections of the renal
cortex area. The fibrotic area was quantified by manually tracing
the blue-stained area; the total scanned area, excluding the tubular
lumen, glomeruli, and vessels, was also quantified using ImageJ
1.38x software (National Institutes of Health, Bethesda, MD). The
fibrotic fraction volume ratio was expressed as the interstitial area
relative to the total area.
Figure 1. Effect of DFO on UUO-induced renal interstitial fibrosis, collagen expression, and macrophage infiltration. (A)
Representative histological findings in tissue stained with Masson’s trichrome 7 days after surgery. (B) Quantitative analysis of renal interstitial fibrosis
at day 7. Sham+VEH (white bar), sham+DFO (light gray bar), UUO+VEH (black bar), and UUO+DFO (gray bar). Results are expressed as the mean 6
SEM. *P,0.05, **P,0.01. n= 12 per group. (C) Analysis of the renal expression of collagen IA, collagen IIIA, and collagen IV. Upper panels:
representative immunoblotting for collagen IA, collagen IIIA, and collagen IV. Lower panels: quantitative analysis of collagen IA, collagen IIIA, and
collagen IV expression normalized to protein staining or tubulin. Results are expressed as the mean 6 SEM. *P,0.05, **P,0.01. n= 12 per group. (D)
Representative immunohistochemistry with F4/80 antibody 7 days after surgery. (E) Quantitative analysis of the F4/80-positive area within the
interstitial area. Results are expressed as the mean 6 SEM. *P,0.05, **P,0.01. n= 12 in each group.
doi:10.1371/journal.pone.0089355.g001
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Measurement of Tissue Iron Concentration
The uncentrifuged crude lysate of the whole kidney was used for
iron measurement. Iron concentrations were measured using a
Metallo Assay kit (AKJ Global Technology, Chiba, Japan) as
previously described [23,29]. The renal iron concentration was
corrected by wet weight and expressed as microgram per gram of
tissue.
Western Blotting
Protein expression was evaluated with western blotting accord-
ing to methods previously described in detail [16]. In brief, tissues
were homogenized in lysis buffer with protease and phosphatase
inhibitors, and the proteins were extracted. The samples were
boiled for 5 min in Laemmli sample buffer, separated using SDS-
PAGE, and transferred to a polyvinylidene fluoride membrane. A
chemiluminescence reagent was used to detect immunoreactive
bands. ImageJ 1.38x software was used for semi-quantitative
densitometric analysis of the bands. The density of each band was
normalized to that of the tubulin band. Non-denatured and non-
reduced samples were used for the detection for collagen IA and
IIIA proteins. The intensities of collagen IA and IIIA bands were
normalized to the intensity of a membrane protein band
(MemCode Reversible Protein Stain kit; Thermo Fisher Scientific
Figure 2. Effect of iron chelation on protein expression related to inflammation and the extracellular matrix. (A) Analysis of the renal
expression of MCP-1 and IL-1b. Upper panels: representative immunoblotting for MCP-1 and IL-1b. Lower panels: quantitative analysis of MCP-1 and
IL-1b expression normalized to tubulin. Results are expressed as the mean 6 SEM. *P,0.05, **P,0.01. n= 12 per group. (B) Quantitative analysis of
aSMA expression. Results are expressed as the mean 6 SEM. *P,0.05, **P,0.01. n= 12 per group. (C) Representative immunochemistry results for
aSMA expression in kidney sections. (D) Quantitative analysis of fibronectin expression normalized to tubulin. Results are expressed as the mean 6
SEM. *P,0.05, **P,0.01. n= 12 per group. (e) Representative immunochemistry results for fibronectin expression in kidney sections.
doi:10.1371/journal.pone.0089355.g002
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Inc., Waltham, MA). The antibodies were used at the following
dilutions: anti-collagen IA (1:100), anti-collagen IIIA (1:250), anti-
collagen IV (1:500), anti-MCP-1 (1:100), anti-IL-1b (1:250), anti-
aSMA (1:1500), anti-fibronectin (1:500), anti-p22phox (1:250), anti-
NOX4 (1:500), TGF-b1 (1:250), anti-phospho Smad3 (1:250),
anti-total Smad3 (1:1000), anti-TfR (1:1000), anti-DMT1 (1:250),
anti-FPN (1:500), anti-FTH (1:250), anti-FTL (1:250), and anti-
tubulin (1:1000).
Immunohistochemistry
Paraffin-embedded kidney samples were sectioned, deparaffi-
nized, and processed with antigen retrieval in 10 mM citrate
buffer at 95uC for 10 min or 0.05% trypsin in phosphate-buffered
saline at 37uC for 20 min. The sections were then incubated with
primary antibody at 4uC overnight. Antibody distribution was
visualized using a streptavidin-biotin complex assay and a DAB
substrate kit (LSAB+ Kit Universal; Dako Japan, Tokyo, Japan).
To evaluate renal macrophage infiltration, 10 fields were
Figure 3. Effect of iron reduction on oxidative stress in the kidneys of mice with UUO. (A) Renal NADPH activity. Data are expressed as the
mean 6 SEM. *P,0.05. n=4–6 per group. (B) Immunoblot analysis for p22phox and NOX4 protein expression. Upper panels: representative
immunoblotting for p22phox and NOX4 expression. Lower panels: quantitative densitometry analysis of p22phox and NOX4 normalized to tubulin.
Values are expressed as the mean 6 SEM. *P,0.05, **P,0.01. n=12 per group. (C) Representative immunohistochemical staining of p22phox
expression.
doi:10.1371/journal.pone.0089355.g003
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randomly selected in the renal cortex area, and the macrophage-
positive area was expressed as a percentage of the whole area,
excluding the tubular lumen, glomeruli, and vessels, using ImageJ
1.38x software analysis. The following antibodies were used: anti-
F4/80 (1:500), anti-aSMA (1:200), anti-fibronectin (1:100), anti-
p22phox (1:100), anti-TfR (1:200), anti-DMT1 (1:100), anti-FPN
(1:100), anti-FTH (1:100), and anti-FTL (1:100).
Measurement of NADPH Oxidase Activity
NADPH oxidase activity was measured as previously described
[16,23]. Briefly, the kidney sample was weighed, immediately
homogenized in lysis buffer, and then sonicated for 3 s. NADPH
substrate (100 mM) was added to a renal suspension with lucigenin
(10 mM). Luminescence was measured every second for 60 min in
a plate reader (SpectraMax Paradigm FilterMaxF3; Molecular
Devices Japan, Tokyo, Japan). NADPH activity was expressed as
relative luminescence units normalized to the protein concentra-
tion.
Statistical Analysis
Data are shown as the mean 6 standard error of the mean
(SEM). For comparisons among 4 groups, the significance of each
difference was evaluated by post-hoc test using the Tukey-Kramer
method. P-values ,0.05 were considered statistically significant.
Results
Characteristics of the mice: Body Weight, Kidney Weight,
Hematological Parameters, and Iron Concentration
Mice from the 4 groups were examined after treatment with
DFO or vehicle. As shown in Table 1, there were no differences in
body weight, hemoglobin levels, and hematocrit levels among the
4 groups. The right kidney weights of UUO+VEH and UUO+
DFO mice were significantly greater than those of sham+VEH
and sham+DFO mice. On the other hand, the left kidney weights
of UUO+VEH mice were lighter than those of sham+VEH or
sham+DFO mice. The reduced left renal weight in UUO mice
was restored by treatment with DFO. The renal iron concentra-
tion was significantly higher in UUO mice treated with vehicle,
and treatment with DFO reduced the renal iron content in UUO
mice.
Effect of DFO Administration on UUO-induced Renal
Interstitial Fibrosis
To examine renal fibrosis induced by UUO, we performed
Masson’s trichrome staining. Seven days after surgery, the
progression of renal interstitial fibrosis was greater in UUO+
VEH mice (3.5060.43%) than in sham+VEH and sham+DFO
mice (0.3460.06% and 0.2860.03%, respectively; sham vs.
UUO+VEH, P,0.01). Fibrotic progression in UUO mice was
mitigated by DFO treatment (1.7960.39%; P,0.01 vs. UUO+
VEH) (Fig. 1A). Consistent with these morphological changes, the
expression of collagen I, III, and IV was approximately 2.0-fold
higher in the kidneys of UUO mice treated with vehicle, but this
increase was attenuated to the expression level in sham mice when
UUO mice were treated with DFO (UUO+VEH vs. UUO+DFO,
P,0.05) (Fig. 1B).
Renal Interstitial Macrophage Infiltration and
Inflammatory Cytokines
To investigate the effect of iron chelation on inflammation in
UUO-induced renal interstitial fibrosis, we analyzed macrophage
infiltration by immunohistochemistry and cytokine expression by
western blot. An increase in the increment area of interstitial
macrophage infiltration was observed in UUO+VEH mice
(9.1761.73%; P,0.01 vs. sham+VEH, 0.7460.11%; sham+
DFO, 0.7560.05%), but was significantly reduced in UUO+
DFO mice (4.1760.46%; P,0.01 vs. UUO+VEH) (Fig. 1C).
Figure 4. Effect of DFO on the UUO-induced acceleration of TGF-b-Smad pathway. (A) Upper panels: representative immunoblotting for
TGF-b1 expression. Lower panels: quantitative evaluation of TGF-b1 protein expression at day 7. Results are expressed as the mean 6 SEM. *P,0.05,
**P,0.01. n= 12 in each group. (B) Upper panel: representative western blots of phopsho-Smad3, total-Smad3, and tubulin. Lower panel:
quantification of western blots. Results are expressed as the mean 6 SEM. *P,0.05, **P,0.01. n= 12 per group.
doi:10.1371/journal.pone.0089355.g004
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Consistent with attenuated macrophage infiltration, the 6-fold
increase in MCP-1 and 3-fold increase in IL-1b protein expression
in the kidneys of UUO mice were reduced by half when UUO
mice were treated with DFO (P,0.01 and P,0.05, respectively,
vs. UUO+VEH) (Fig. 2A).
Effect of DFO on Myofibroblasts and Extracellular Matrix
Expression
Consistent with the histological findings, the expression of
aSMA and fibronectin was increased 6.0-fold and 2.0-fold,
respectively, in the kidneys of UUO+VEH mice, compared to
expression in sham+VEH mice and sham+DFO mice (P,0.01 vs.
UUO+VEH). DFO treatment suppressed the UUO-induced
interstitial accumulation of myofibroblasts and of the extracellular
matrix protein (P,0.01, UUO+DFO vs. UUO+VEH; Fig. 2B).
Iron Chelation Reduced UUO-induced Renal Oxidative
Stress
Iron chelation decreases oxidative stress, and the progression of
renal fibrosis is associated with oxidative stress. Therefore, we
examined the effect of DFO treatment on UUO-induced oxidative
stress. As shown in Fig. 3A, the renal NADPH oxidase activity of
UUO mice was increased 2.3-fold (P,0.01 vs. sham+VEH or
sham+DFO); this augmentation was abrogated by DFO treatment
Figure 5. Changes in protein expression related to iron metabolism in the kidneys of mice with UUO. (A) Representative immunoblots
for transferrin receptor (TfR), divalent metal transporter-1 (DMT1), ferroportin (FPN), ferritin heavy chain (FTH), and ferritin light chain (FTL). (B)
Quantitative densitometry analysis of TfR, DMT1, FPN, FTH, and FTL normalized to tubulin. Values are expressed as the mean 6 SEM. *P,0.05, **P,
0.01. n= 12 per group. (C) Representative immunohistochemical staining and localization of TfR, DMT1, FPN, FTH, and FTL.
doi:10.1371/journal.pone.0089355.g005
Effect of Deferoxamine on Renal Fibrosis
PLOS ONE | www.plosone.org 7 February 2014 | Volume 9 | Issue 2 | e89355
(P,0.05 vs. UUO+VEH). In immunohistochemical analysis,
expression of p22phox was significantly increased in the renal
tubules of UUO mice treated with vehicle or DFO; this increase
was mitigated by DFO treatment. Similarly, the expression of
p22phox in the kidney was 8.4-fold higher in UUO+VEH mice (P,
0.01 vs. sham+VEH or sham+DFO); the expression of p22phox in
UUO mice decreased by half when they were treated with DFO
(P,0.01 vs. UUO+VEH) (Fig. 3B and C). Finally, NOX4
expression in the kidney was 1.5-fold higher in UUO mice (P,
0.01 vs. sham+VEH and sham+DFO). There was no difference in
renal NOX4 expression in UUO+VEH and UUO+DFO mice
(Fig. 3B).
Effect of Reduced Iron Content on the TGF-b-Smad
Signaling Pathway
TGF-b-Smad signaling is a crucial pathway in the development
of tissue fibrosis. Therefore, we examined whether the protective
effect of iron reduction by DFO on UUO-induced renal fibrosis
was associated with the TGF-b-Smad pathway. Renal TGF-b1
expression increased 5.7-fold in vehicle-treated UUO mice, when
compared with expression in vehicle- or DFO-treated sham mice
(P,0.01). DFO treatment reduced TGF-b1 expression to 77% of
the level in UUO+VEH (Fig. 4A). The expression of phosphor-
ylated and total Smad3 was upregulated 4.0-fold and 3.6-fold,
respectively, in vehicle-treated UUO mice. DFO treatment
reduced phosphorylated Smad3 levels to 76% of the level in
UUO+VEH. DFO treatment did not alter total Smad3 expression
in UUO mice (Fig. 4B).
Changes in the Expression of Iron Transporters, Ferritin,
and Urinary Iron Excretion in UUO-induced Fibrotic
Kidney
In the kidneys of UUO+VEH mice, TfR expression decreased;
meanwhile, DMT1 and FPN expression increased 2.1-fold and
1.5-fold, respectively. Treatment of UUO mice with DFO restored
the expression of TfR to the level in sham+VEH mice and reduced
FPN expression by half. DFO treatment itself increased TfR
expression by 3.7-fold but did not change the expression of DMT1
and FPN in the kidneys of sham mice. FTH and FTL expression
in the kidney decreased by half when sham mice were treated with
DFO. FTH and FTL expression was approximately 1.5-fold
higher in UUO mice than in sham mice. Ferritin levels in UUO
mice treated with DFO were similar to those in sham mice (Fig. 5A
and B). In immunohistochemical analysis, the iron transporters
and ferritin were primarily expressed in the renal tubules (Fig. 5C).
Discussion
In the present study, we showed that iron deprivation induced
by DFO treatment suppressed renal interstitial fibrosis as well as
the expression of collagen I, III, and IV in mice with UUO. Iron
chelation also prevented macrophage infiltration and the induc-
tion of inflammatory cytokines. We also showed that DFO
diminished renal oxidative stress by inhibiting p22phox upregula-
tion and TGF-b-Smad signaling activation in UUO mice. Thus,
the protective effect of iron chelation in UUO-induced renal
interstitial fibrosis involves the inhibition of oxidative stress,
inflammation, and pro-fibrotic signaling.
Iron participates directly in tissue fibrosis, and iron reduction
has been shown to suppress fibrotic changes in the liver. Patients
with iron overload diseases, such as thalassemia, or patients who
receive numerous blood transfusions often present with hepatic
fibrosis. In these patients, the progression of liver fibrosis can be
delayed or prevented by iron chelation therapy [30–32]. Similarly,
iron reduction by phlebotomy or a low-iron diet suppresses hepatic
fibrosis in patients with hepatitis C [33–35] and suppresses non-
alcohol fatty liver disease [36]. However, these liver diseases are
generally not thought to be iron-related.
The ameliorating effects of iron reduction on tissue fibrosis have
been examined in various experimental and animal models.
Ishizaka et al. showed that DFO treatment prevented cardiovas-
cular fibrosis induced by AngII by inhibiting oxidative stress and
macrophage infiltration [13,14]. They also reported that iron
chelation suppressed AngII-induced TGF-b1 upregulation in the
kidney [19] and heart [37]. A low-iron diet attenuated the
expression of TGF-b1 and the upregulation of collagen III in a
CKD rat model [21]. Indeed, TGF-b1 is a well-known major pro-
fibrotic stimulator of collagen and extracellular matrix production
in a variety of cell types [38]. Smad is a downstream target of
TGF-b1 signaling, and the TGF-b1-Smad pathway is critical in
fibrosis development [39]. In the kidney, TGF-b1 expression
increased with UUO [40], and treatment with a neutralizing
antibody to TGF-b1 ameliorated UUO-induced renal interstitial
fibrosis [41]. Disruption of Smad3 diminished UUO-induced
renal tubulointerstitial fibrosis, suggesting that Smad3 plays a
crucial role in the development of fibrosis in kidney diseases
[42,43]. In the present study, UUO induced TGF-b1 expression
and Smad3 phosphorylation. The activation of TGF-b1-Smad3
signaling in UUO mice were inhibited by the iron chelator DFO,
leading to the amelioration of UUO-induced renal fibrosis. Thus,
the inhibition of TGF-b1-Smad3 signaling by iron reduction
contributes to the prevention of UUO-induced renal interstitial
fibrosis. In addition, activated fibroblasts (also known as myofi-
broblasts) that express aSMA are a major source of extracellular
matrix production [44]. In this study, UUO-induced aSMA
expression was markedly reduced by DFO treatment. Further-
more, fibroblasts were activated by various cytokines including
TGF-b [45], and TGF-b signaling was inhibited by DFO.
Therefore, DFO may inhibit fibrosis by inhibiting the TGF-b
pathway activation in fibroblasts.
UUO induces macrophage infiltration in the renal tubulointer-
stitium. The macrophages produce inflammatory cytokines,
resulting in a detrimental cycle of tubulointerstitial fibrotic change
Figure 6. The schema of the proposed mechanism for the
inhibitory effects of DFO on UUO-induced renal interstitial
fibrosis.
doi:10.1371/journal.pone.0089355.g006
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[46]. Iron reduction reduces macrophage infiltration and inflam-
matory cytokines in the aorta and heart of Dahl-salt sensitive rats
[15], a CKD model induced by 5/6 nephrectomy [21], and in the
adipose tissue of KKAy mice [16]. Consistent with these findings,
DFO treatment mitigated macrophage infiltration and the
production of inflammatory cytokines such as MCP-1 and IL-1b
in UUO mice, which contributed to the preventive effect of iron
reduction on inflammation.
The epithelial mesenchymal transition (EMT) contributes to the
development of renal interstitial fibrosis induced by UUO [47].
Epithelial cells de-differentiate and lose their epithelial cell surface
markers, and myofibroblasts differentiate into fibroblasts. The
altered cells express mesenchymal marker proteins such as aSMA
and fibronectin. Similar to its role in fibrosis, TGF-b1-Smad3
signaling is a key mediator for triggering EMT in vivo [42].
Therefore, we postulate that the reduction of UUO-induced renal
aSMA and fibronectin expression by DFO suppresses renal
fibrosis by inhibiting EMT via TGF-b-Smad signaling. However,
several studies have shown that EMT does not result in the
generation of interstitial myofibroblasts in fibrotic renal disease
models, and therefore the role of EMT has remained controversial
[48]. Therefore, further studies are necessary to confirm the role of
EMT in renal interstitial fibrosis.
Oxidative stress is considered a contributing factor in the
progression of CKD, including renal fibrosis [49]. UUO, a
widely used experimental model of renal fibrosis, induces
oxidative stress; oxidative stress plays a crucial role in the
pathogenesis of UUO in the kidney [50]. Iron causes oxidative
stress through its catalysis of the Fenton reaction, and iron-
derived oxidative stress participates in various diseases. Indeed,
iron reduction can ameliorate pathological states, not only in
heredity hemochromatosis, but also in non-iron overload
diseases. In addition to inducing oxidative stress through the
Fenton reaction, iron affects NADPH oxidase, which produces
superoxide. UUO increased the renal expression of NADPH
oxidase subunits such as p22phox, p47phox, and p67phox [51].
Our study group and others have demonstrated that iron
chelators suppress oxidative stress by inhibiting p22phox expres-
sion and NADPH oxidase activity in diabetic obese mice [16],
mice with diabetic nephropathy [23], a murine model with local
inflammation [52], and in endothelial cells [53]. Consistent with
these findings, iron deprivation by DFO suppressed the increase
in NADPH oxidase activity and p22phox expression in a UUO
mouse model, thus providing insight into the mechanism by
which iron reduction affects renal fibrosis through decreased
oxidative stress. Sugiyama et al. showed that UUO-induced
p22phox was expressed in renal tubules [51]. We previously
showed that dietary iron restriction reduced the upregulation of
renal p22phox expression in renal proximal tubules of db/db mice
[23]. Furthermore, p22phox expression was colocalized in F4/80-
or CD 68-positive cells that were obtained from the fat of
diabetic and obese mice or from human atherosclerotic
coronary arteries [16,54]. Therefore, the reduction of UUO-
induced renal macrophage infiltration after DFO treatment may
have further decreased NADPH oxidase activity. However,
various cell types, such as fibroblasts, endothelial cells,
podocytes, and pericytes/perivascular fibroblasts, produce
NADPH oxidase, which is involved in the progression of renal
fibrosis. Further studies are required to elucidate whether DFO
affects NADPH oxidase production in various cell types.
The kidney is thought to participate in iron homeostasis because
renal tubular cells express iron importers, TfR [55] and DMT1
[56,57], and an iron exporter, FPN [58]. Expression of these iron
transporters was altered in diabetic nephropathy [23,59], 5/6
nephrectomy [21], the anemic kidney [60], and kidneys with
AngII infusion [20], indicating an alteration in renal iron
metabolism in these diseases. We observed that iron concentration
was increased in kidney of UUO mice with reduced TfR
expression and increased DMT1 and FPN expression in the renal
proximal tubular cells. In this study, the alterations in iron
transporter expression may be compensatory changes that prevent
renal iron elevation induced by UUO. Additionally, the expression
of heavy and light chain ferritin was also increased in the renal
tubules of UUO mice. In other animal models, ferritin expression
increased in the aorta and heart after AngII infusion [13,14], the
aorta and heart of Dahl salt-sensitive rats [15], the adipose tissue of
KKAy mice [16], and the kidneys of db/db mice with diabetic
nephropathy [23]. Ferritin, an intracellular iron storage protein,
reduces intracellular free iron levels, thereby suppressing catalysis
of the Fenton reaction [61]. Indeed, tissue iron concentration are
also augmented in the aorta and heart after AngII infusion
[13,14], aorta of Dahl salt-sensitive rats [15], and the kidneys of
db/db mice [23]. Accordingly to those, whole kidney iron
concentration and renal ferritin levels were elevated in UUO
mice, and upregulated ferritin levels may be a compensatory
manner as a result of increased free iron levels, thus contributing to
reduced oxidative stress via the Fenton reaction.
Iron chelation by DFO has protective effects in various disease
models, including renal fibrosis. However, several studies have
shown adverse effects of DFO on kidney injury. DFO promotes
HIF-1a activity [25], and HIF-1a activation exacerbates UUO-
induced renal fibrosis via the EMT [26]. In a rat model of
ischemia/reperfusion renal injury, IL-10 infusion protected
against renal injury by inducing lipocalin-2 in an intracellular
iron-dependent manner; the effect of IL-10 were abolished by
DFO treatment [28]. Thus, the effect of DFO on renal injury is
controversial and unresolved. Further studies are necessary to
determine whether iron chelation therapy alleviates or aggravates
tubulointerstitial fibrosis.
In conclusion, iron reduction by DFO prevents renal tubulo-
interstitial fibrosis by inhibiting oxidative stress and TGF-b1-
Smad3 signaling activation. The hypothetical mechanism by
which DFO affects UUO-induced renal interstitial fibrosis is
shown in Figure 6. Iron reduction is a promising therapeutic
strategy for CKD.
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